Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.17, read 2026-11-02
Ethical does not pass the values gate
Price12.75 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-01Read Markup8.93+42.8% to today ✓Distribution gives way to Markup after a 1069% rise in 17 weeks
2026-07-02Read Distribution0.76+1,569.1% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Alight Inc holds its Markup at $12.75. The statistical read favours the sellers, held for 56 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 56 days
Price at the screen
$12.75
Valuation
N/A trailing · 2.26 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.59
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
46.39%
Below 33%
Interest-bearing debt is 46.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
14.45%
Below 49%
Money owed to the company is 14.4% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Alight's business is in a permissible area, but its interest-bearing debt is about 46% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ALIT's ethical verdict changes
Today ALIT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.55x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Employee platform trades cheap but shows no edge
Picture a benefits admin service that helps workers navigate healthcare and retirement across borders. The price sits far below our fair value with a forward multiple of just 3.3x, yet revenue is already shrinking 3 percent and the company posts a 138 percent negative profit margin alongside negative 117 percent return on equity. No moat exists, so the low multiple reflects a business that is losing ground rather than a bargain waiting to recover.
We pass because the ethical screen clears but nothing else does. Shrinking sales and heavy losses point to structural weakness in a competitive field where bigger players already dominate cloud benefits software. Analyst targets sit higher yet fail to offset the absence of any durable advantage that could turn the numbers around.
Risks centre on further revenue erosion and the chance that low earnings multiples simply mark peak losses rather than an entry point. Execution on the cloud platform will need to improve sharply just to stabilise the base. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ALIT trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Markup$8.93+0.0%Entry 19
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 69% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 87%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (4 analysts) rates it buy, with a mean price target of $2. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$8.93+0.0%Entry 18
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 69% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 87%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (4 analysts) rates it buy, with a mean price target of $2. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup · changed$8.93+5.6%Entry 17
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 69% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 87%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (4 analysts) rates it buy, with a mean price target of $2. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Distribution$8.46+0.0%Entry 16
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 69% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 87%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (4 analysts) rates it buy, with a mean price target of $2. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Distribution$8.46+0.0%Entry 15
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 69% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 87%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (4 analysts) rates it buy, with a mean price target of $2. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Distribution$8.46-8.2%Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 8.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 69% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 87%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (4 analysts) rates it buy, with a mean price target of $2. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Distribution$9.22+0.0%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 69% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 87%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (4 analysts) rates it buy, with a mean price target of $2. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Distribution$9.22+0.0%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 69% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 87%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (4 analysts) rates it buy, with a mean price target of $2. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Distribution$9.22+0.0%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 69% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 87%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (4 analysts) rates it buy, with a mean price target of $2.
2026-10-19Distribution$9.22-1.5%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 69% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 87%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (4 analysts) rates it buy, with a mean price target of $2.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.